BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 21234353)

  • 1. Focus on adoptive T cell transfer trials in melanoma.
    Hershkovitz L; Schachter J; Treves AJ; Besser MJ
    Clin Dev Immunol; 2010; 2010():260267. PubMed ID: 21234353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
    Svane IM; Verdegaal EM
    Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
    Considine B; Hurwitz ME
    Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes in melanoma.
    Lee S; Margolin K
    Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cell therapy for the treatment of patients with metastatic melanoma.
    Rosenberg SA; Dudley ME
    Curr Opin Immunol; 2009 Apr; 21(2):233-40. PubMed ID: 19304471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive T-cell transfer in melanoma.
    Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
    Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
    Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
    J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
    Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
    Mayor P; Starbuck K; Zsiros E
    Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.
    Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
    Cancer Immunol Immunother; 2014 Oct; 63(10):1061-71. PubMed ID: 24993563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
    Joseph RW; Peddareddigari VR; Liu P; Miller PW; Overwijk WW; Bekele NB; Ross MI; Lee JE; Gershenwald JE; Lucci A; Prieto VG; McMannis JD; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Hwu P; Radvanyi LG
    Clin Cancer Res; 2011 Jul; 17(14):4882-91. PubMed ID: 21632855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Therapy and Cytokine Treatments for Melanoma.
    Borgers JSW; Haanen JBAG
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):129-144. PubMed ID: 33759770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.